title: Reversible attenuation of glutamatergic transmission in hippocampal CA1 neurons of rat brain slices following transient cerebral ischemia.
abstract: The present experiments were conducted to determine the time course of synaptic dysfunction in the vulnerable regions of the post-ischemia hippocampus. Following transient cerebral ischemia, neurons in the CA1 subfield of the hippocampus undergo a delayed degeneration that develops about 48 h after reperfusion. We have shown previously that CA1 glutamatergic transmission is decreased in the CA1 subfield well before any morphological deterioration of the CA1 cells is visible under the light microscope. However, it is unknown whether a time window exists after insult in which attenuated synaptic activity may be restored to normal levels. We show here that evoked CA1 somatic population spikes and dendritic field potential responses decline progressively after reperfusion in the CA1 subfield, such that by 72 h post-insult, the challenged neurons are unable to elicit evoked excitatory responses. This attenuation of synaptic transmission was confined to the vulnerable neurons of the hippocampus, however, as the evoked responses in the dentate gyrus displayed amplitudes that were not significantly diminished from sham control after challenge. In brain slices obtained from 24 h post-ischemia rats with significantly impaired CA1 somatic responses, the application of 5 or 50 microM of the potassium channel blocker 4-aminopyridine (4-AP) restored the magnitude of the evoked excitatory response to control values. At 36 h post-ischemia, the decreased CA1 evoked responses could be partially improved by 4-AP, but not to control levels. Based upon these results, we conclude that the decreased CA1 synaptic activity at 24 h post-ischemia is potentially reversible, and suggest that 4-AP improves the CA1 synaptic responses at least in part by improving transmitter release at post-ischemia glutamatergic synapses.
authors.affiliation: Playfair Neuroscience Unit, 399 Bathurst Street, Toronto, Ontario, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: G F
authors.initials: GF
authors.lastname: Tian
authors.forename: M C
authors.initials: MC
authors.lastname: Wallace
authors.forename: J H
authors.initials: JH
authors.lastname: Eubanks
mesh_terms: D015761:4-Aminopyridine / Q000627:therapeutic use*; D000818:Animals; D018891:Dentate Gyrus / Q000187:drug effects / Q000473:pathology; D004569:Electroencephalography / Q000187:drug effects; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D018698:Glutamic Acid / Q000502:physiology*; D006624:Hippocampus / Q000187:drug effects* / Q000473:pathology; D066298:In Vitro Techniques; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009474:Neurons / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D009435:Synaptic Transmission / Q000187:drug effects*
chemical_list: D018698:Glutamic Acid; D015761:4-Aminopyridine